Viromers go British
The offering will feature the reagents Viromer®Blue and Viromer®Green, critical materials for the work with RNAi. Christian Reinsch, PI at Lipocalyx says: “We knew it is good stuff - but still, it was quite rewarding for us to see Viromers working in other people’s hands. The labs out there used it in challenging experiments and the reality check went really well”.
For the marketing in the UK, Lipocalyx has partnered with Voicentric, a communicator specialized in the life science sector. Steffen Panzner, CEO of Lipocalyx comments: “Expanding the marketing outside Germany was the thing to do and with Voicentric we found a like-minded partner. When we reach out to the scientist, listening and developing solutions is of the same importance to us as presenting the Viromer story. In that regard, we didn’t need to explain much to Voicentric”.
Lipocalyx GmbH, a drug delivery company based in Halle/Saale, Germany started its venture in August 2011 to create entirely novel polymer-based transfectants for oligonucleotides. The team has a strong background in siRNA transfection and chemistry. Lipocalyx received seed financing by IBG RKF II, managed by Goodvent in Magdeburg and High-Tech Gründerfonds (HTGF) in Bonn.
Voicentric Ltd is a marketing agency which specialises in Life-Science and similarly high-tech and research based disciplines. People at Voicentric communicate complex messages - predominantly by telephone - about products and services which improve and facilitate thier research. The company has formed strong ties with the University of Durham.
Dr. Steffen Panzner